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ABSTRACT
Central retinal artery occlusion (CRAO) is an
infarction to the retina that results in acute,
frequently severe vision loss. Long-term
complications such as ocular
neovascularization (ONV) can occur and result
in neovascular glaucoma and vitreous
hemorrhage. Recent studies have explored
acute hyperbaric oxygen (HBO) therapy as a
promising treatment for CRAO to improve
long-term vision potential; however, its effects
on CRAO complications have not been well
characterized. This study was conducted to
better characterize the effects of HBO therapy
on complications from CRAO. We present a
unique case of ONV in an eye within 1 month
after successfully completing acute HBO
therapy for a CRAO, highlighting the
importance of routine monitoring in this
unique population.
Keywords: Central retinal artery occlusion;
Glaucoma; Hyperbaric oxygen; Neovascular
glaucoma
INTRODUCTION
Occlusion of the central retinal artery can cause
retinal ischemia, infarction, and acute vision
loss [1]. Similar to ischemic cerebrovascular
accidents, an embolic etiology is commonly
from either a carotid artery or cardiac plaque,
the latter often from atrial fibrillation [1, 2].
Recent studies have shown that the most
meaningful risk factor for central retinal artery
occlusion (CRAO) is an ipsilateral carotid artery
stenosis; thus early imaging of the greater neck
vessels is essential for management [3]. Ocular
neovascularization (ONV) has been reported to
occur in up to 19% of cases [4–7]. This can
involve neovascularization of the iris, the optic
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disc, or the surrounding retina. ONV onset
following CRAO has been described anywhere
from 2 weeks to 2 years after the original event,
although the majority occur between 8 and 12
weeks afterward [6, 8]. ONV can further
decrease vision and cause pain if neovascular
glaucoma develops. Currently, there is a paucity
of proven clinical treatments for CRAO.
Treating CRAO with hyperbaric oxygen
therapy (HBO) has been reported in animal
studies and small series; however, we lack large
controlled human studies [9–14]. Its impact on
downstream complications such as ONV is
currently not well understood; thus, there is
great interest in further investigation within
this unique patient population.
CASE REPORT
A 70-year-old African male reported to the
emergency department with decreased vision in
the right eye (RE) andheadache. His pastmedical
history included hypertension, hyperlipidemia,
diabetes mellitus, long-term poor vision in the
left eye (LE) from previous ocular trauma, and
pseudophakia of the RE. He described
intermittent darkening of RE vision for the past
4 days along with a mild headache; however, he
was able to read small print until 24 h prior to
admission, when his RE vision decreased
abruptly. He denied recent weight loss, fever,
myalgia, or jaw claudication. He had an
erythrocyte sedimentation rate of 32 mm/h
(normal: 0–10 mm/h), C-reactive protein of
1.6 mg/L (normal\5.00 mg/L), and platelet
count of 286 k/cmm. His best-corrected visual
acuity (BCVA)was 2/200 in the REwith eccentric
fixation and light perception in the LE.
Intraocular pressure (IOP) was 15 mmHg in the
RE. Anterior segment examination revealed a
normal-appearing RE with a deep anterior
chamber depth and no rubeosis or cell, while
the LE had the appearance of phthisis bulbi.
Gonioscopy showed that the RE angle was open
to trabecular meshwork without
neovascularization of the angle. Fundus
examination showed a normal-appearing optic
nerve in the RE, patchy retinal edema and
whitening throughout the macula, and a cherry
red spot, and normal-appearing peripheral
vasculature (Fig. 1). His clinical presentation
was most consistent with intermittent episodes
of amaurosis fugax beginning 4 days prior with
onset of CRAO 1 day prior to presentation.
The patientwas admitted for stroke evaluation
as well as acute HBO therapy. The patient was
initiated on daily clopidogrel therapy for
secondary stroke prevention, and adjustments
were made to his medication regimen to better
control hypertension, hyperlipidemia, and
diabetes mellitus. Magnetic resonance imaging
and angiography of the brain revealed no acute
findings, transthoracic echocardiography with
bubble study did not reveal any cardiac septal
defects, plaques, or emboli, and cardiac telemetry
was unconcerning. MR angiography of the neck
revealed 60%narrowing of a short segment of the
distal internal carotid artery at the level of the C2
vertebrate. Humphrey 24-2 visual field testing
revealed a small inferior central scotoma in the RE
consistent with the known area of retinal edema
(data not shown). The patient received two HBO
treatments of 4 h duration each day for 5 days
total as per our protocol. On the second day of
hospitalization, fluorescein angiogram (FA) of the
REwasobtainedandshowedpoorperfusiontothe
macula (Fig. 2). After completion of the 5-day
protocol, thepatientwasdischargedtohomewith
BCVA of 2/200 RE and IOP of 11 mmHg RE. Per
our protocol, we monitor all CRAO for
development of neovascular glaucoma up to
1 year following the initial insult.
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Subsequently, the patient followed up with
an outside eye care provider 24 days after the
onset of symptoms and was found to have
elevated IOP in the RE. He was started on
dorzolamide/timolol drop twice per day and
referred to our retina service 2 days later. His
BCVA was 20/400 and IOP was 28 in the RE
upon presentation. Anterior examination
revealed neovascularization of the iris and
angle on gonioscopy. Posterior examination
showed neovascularization of the optic disc
with extensive pigmentary alteration in the
macula, but no retinal whitening. Optical
coherence tomography showed retinal
atrophy in the macula, and FA showed retinal
ischemia and leakage from neovascularization
of the optic disc (Fig. 3). The diagnosis of
neovascular glaucoma (NVG) secondary to
CRAO was made, and the patient underwent
pan-retinal photocoagulation to the RE. One
month later, his RE vision and IOP had
improved to 20/100 and 20 mmHg,
respectively. His neovascularization had fully
regressed, and he has remained stable for over
1 year of follow-up with IOP of 12 RE off
topical medications.
Fig. 1 CRAO in right eye of patient. Images obtained
1 day after presentation include fundus photography
exhibiting cherry red spot in macula (a), red-free photog-
raphy (b), and OCT through fovea showing extensive
inner retinal edema (c). Humphries 24-2 visual ﬁeld
testing revealed nonspeciﬁc defects and a small inferior
central scotoma in the right eye consistent with known
area of retinal insult (d). CRAO central retinal artery
occlusion, OCT optical coherence tomography
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Compliance with Ethics Guidelines
Informed consent was obtained from the
patient for being included in this study.
DISCUSSION
ONV is a serious complication following CRAO
with reported incidence ranging up to 19% [1].
There is evidence that CRAO with more severe
ischemia may have a higher risk of
neovascularization [4–7]. Central retinal vein
occlusions have higher rates of
neovascularization when there is more
ischemia present initially. The literature is
lacking in any large or systematic analysis of
the complication rate after treatment with HBO
or, for that matter, with rapid reperfusion by
other means such as digital massage, anterior
chamber paracentesis, or hypercapnia.
A proposed mechanism of HBO therapy is
that the elevated blood oxygen content
achieved through HBO allows oxygen to
diffuse more effectively into the retina from
choroidal circulation. The inner retina that
normally relies on central retinal artery
perfusion receives sufficient oxygenation from
both the choroidal vasculature and any residual
retinal artery perfusion to survive until the
central retinal artery recanalizes [15, 16]. This
is predicated on applying the HBO while the
retinal ischemia is still reversible, typically
within the first 2 days after the inciting event.
The vision in our patient did improve with
HBO, but remained poorer than it was prior to
the CRAO, and far poorer than that of many
other eyes at our institution that undergo
prompt HBO therapy for CRAO. This was most
likely due to our inability to fully reverse the
initial ischemic retinal insult. He probably
sustained a large component of irreversible
macular ischemia from the series of transient
amaurosis episodes and the 24 h of CRAO prior
to onset of HBO therapy. This may well be the
reason for his development of ONV and it
would have happened regardless of whether he
underwent HBO therapy. His ONV developed a
little less than a month after the CRAO, within a
time range that has certainly been reported after
untreated CRAO, although it is on the earlier
side of the spectrum.
A potential mechanism beyond just
profound initial ischemia may involve the
HBO therapy itself. The acute HBO protocol
for CRAO at our institution during the time of
this study included two treatments per day for a
Fig. 2 FA of right eye with CRAO. Images obtained 1 day
after presentation show macular ischemia with normal
peripheral retinal perfusion. Timing of the study is shown
in the upper right corner of each image (in minutes). CRAO
central retinal artery occlusion, FA ﬂuorescein angiogram
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total of ten sessions or 5 days, which is derived
from previous studies and treatment algorithms
proposed by other groups [9, 12]. Even though
the patient initially presented possibly outside
of the 24 h treatment window, we felt
compelled to offer HBO to provide as much
potential as possible for him to recover vision in
his RE in the monocular setting. ONV is driven
by vascular endothelial growth factor (VEGF)
released from ischemic retinal tissue that is not
dead. When initial infarction occurs, the retina
declines to an ischemic state, and VEGF begins
to be released. Over time, the ischemic retina in
an untreated patient declines further into
necrosis and atrophy; thus, VEGF secretion is
stopped. It is conceivable that in the
HBO-treated patient, the ischemic phase is
prolonged by the improvement in retinal
oxygen saturation, thus enhancing VEGF
release and potentially worsening ONV
(Fig. 4). Further clinical studies will be
essential to further elucidate this process.
CONCLUSION
Ultimately, HBO remains a controversial
treatment modality for CRAO, a condition for
which we are still without a proven and widely
Fig. 3 Imaging from our patient 24 days after CRAO.
Fundus photo shows improved retinal whitening and
pigmentary mottling throughout (a). FA shows persistent
retinal ischemia along with leakage from neovasculariza-
tion of the disc (b). Enlarged images better characterize
neovascularization of the disc (A0) and FA leakage (B0).
Inner retinal edema has improved, but still mildly present
along with signiﬁcant atrophy (c). CRAO central retinal
artery occlusion, FA ﬂuorescein angiogram
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accepted means of improving vision. The NVG
was treated effectively in this patient, and his
current level of vision in the RE is most likely
due to the original CRAO rather than the
subsequent ONV. This case does underscore,
however, that patients undergoing HBO for
CRAO may need to be followed more closely
for the development of secondary CRAO
complications such as ONV compared to those
who have not undergone HBO.
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